B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin)

International Journal of Cancer

Volumn 131, Issue 7, 2012, Pages 1499-1508

  Kammertoens, Thomas ^a   Qin, Zhihai ^a,d   Briesemeister, Dana ^a   Bendelac, Albert ^b   Blankenstein, Thomas ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d INSTITUTE OF BIOPHYSICS   (China)

Author keywords

chemical carcinogenesis; immune deficient mice; immunosurveillance; methylcholanthrene

Indexed keywords

3 METHYLCHOLANTHRENE; FAS LIGAND; INTERLEUKIN 4; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC DRIFT; IMMUNOCOMPETENCE; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; ENVIRONMENT; FAS LIGAND PROTEIN; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NATURAL KILLER T-CELLS; PERFORIN; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864453237     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27411     Document Type: Article

References (50)

1. DiGiovanni J,. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54: 63-128.
2. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
3. Salerno RA, Whitmire CE, Garcia IM, Huebner RJ,. Chemical carcinogenesis in mice inhibited by interferon. Nat New Biol 1972; 239: 31-2.
4. Rous P, Friedewald WF,. The carcinogenic effect of methylcholanthrene and of tar on rabbit papillomas due to a virus. Science 1941; 94: 495-6.
5. Woodruff M, Speedy G,. Inhibition of chemical carcinogenesis by Corynebacterium parvum. Proc R Soc Lond B Biol Sci 1978; 201: 209-15.
6. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T,. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 2001; 22: 599-605.
7. Creau-Goldberg N, Salomon JC,. Immunotherapy of primary methylcholanthrene-induced mouse tumours by intratumoral BCG. Br J Cancer 1980; 41: 541-52.
8. Roe FJ, Grant GA,. Inhibition by germ-free status of development of liver and lung tumours in mice exposed neonatally to 7,12-dimethylbenz(a)anthracene: implications in relation to tests for carcinogenicity. Int J Cancer 1970; 6: 133-44.
9. Marchant J,. The effect of methylcholanthrene and different social conditions on the appearance of breast tumours in NZY mice. Br J Cancer 1966; 20: 210-5.
10. Molomut N, Lazere F, Smith LW,. Effect of audiogenic stress upon methylcholanthrene-induced carcinogenesis in mice. Cancer Res 1963; 23: 1097-101.
11. Baker DG,. Influence of a chronic environmental stress on the incidence of methylcholanthrene-induced tumors. Cancer Res 1977; 37: 3939-44.
12. Konno A, Hishinuma K, Hashimoto Y, Kimura S, Nishimura T,. Dietary restriction reduces the incidence of 3-methylcholanthrene-induced tumors in mice: close correlation with its potentiating effect on host T cell functions. Cancer Immunol Immunother 1991; 33: 293-8.
13. Rashkis HA,. Systemic stress as an inhibitor of experimental tumors in Swiss mice. Science 1952; 116: 169-71.
14. Welsch CW,. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 1985; 45: 3415-43.
15. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD,. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
16. Smyth MJ, Crowe NY, Godfrey DI,. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-63.
17. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI,. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191: 661-8.
18. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H,. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996; 184: 1781-90.
19. Qin Z, Blankenstein T,. A cancer immunosurveillance controversy. Nat Immunol 2004; 5: 3-4; author reply -5.
20. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ,. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008; 105: 652-6.
21. Schreiber TH, Podack ER,. A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. Br J Cancer 2009; 101: 381-6.
22. Stutman O,. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974; 183: 534-6.
23. Stutman O,. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 1979; 62: 353-8.
24. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y,. NKG2D function protects the host from tumor initiation. J Exp Med 2005; 202: 583-8.
25. Smyth MJ,. Clarification of data used in three studies on MCA-induction of sarcoma in mice. Blood 2008; 111: 4419.
26. Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, Horwitz BH, Fox JG,. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol 2003; 162: 691-702.
27. Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G,. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003; 197: 1213-9.
28. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
29. Burnet FM,. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
30. Prehn RT, Main JM,. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769-78.
31. Klein G, Sjogren HO, Klein E, Hellstrom KE,. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20: 1561-72.
32. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD,. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-7.
33. Grant GA, Roe FJ,. Effect of germ-free status and antilymphocyte serum on induction of various tumours in mice by a chemical carcinogen given at birth. Nature 1969; 223: 1060.
34. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH,. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-80.
35. Prehn RT, Bartlett GL,. Surveillance, latency and the two levels of MCA-induced tumor immunogenicity. Int J Cancer 1987; 39: 106-10.
36. Qin Z, Kim HJ, Hemme J, Blankenstein T,. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 2002; 195: 1479-90.
37. de Visser KE, Korets LV, Coussens LM,. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411-23.
38. Hasan M, Polic B, Bralic M, Jonjic S, Rajewsky K,. Incomplete block of B cell development and immunoglobulin production in mice carrying the muMT mutation on the BALB/c background. Eur J Immunol 2002; 32: 3463-71.
39. Klein G, Klein E,. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 1977; 74: 2121-5.
40. Bailey DW,. How pure are inbred strains of mice? Immunol Today 1982; 3: 210-14.
41. Prehn RT,. Immunostimulation of chemical oncogenesis in the mouse. Int J Cancer 1977; 20: 918-22.
42. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM,. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
43. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM,. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72.
44. Rondini EA, Walters DM, Bauer AK,. Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner. Part Fibre Toxicol 2010; 7: 9.
45. Blankenstein T, Qin Z,. Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv Cancer Res 2003; 90: 179-207.
46. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN,. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007; 67: 1062-71.
47. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F,. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-31.
48. Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, Girardi M,. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci USA 2007; 104: 6770-5.
49. Willimsky G, Blankenstein T,. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437: 141-6.
50. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, Jacks T,. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19: 72-85.